Rockeby to market CanDia5 and PePP to Middle East
Australia-listed and Singapore-based biotechnology group Rockeby biomed says it has executed an agreement with United Pharma Marketing UAE for the distribution of both its CanDia5 Candida diagnostic product and PePP hangover remedy to the United Arab Emirates, Qatar, Kuwait and Iran.
With the signing of this contract, United Pharma will be placing the first order of 2,500 packs of CanDia5 for delivery immediately, said Rockeby chief executive Sze-Wee Tan.
"The current CanDia5 pack, which has the European CE Mark approval, can be sold within the region and does not require additional modification or re-registration," he said. The company is marketing the product as an alternative method to diagnose Candida.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze